Tennessee is currently home to 1915 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Nashville, Memphis, Knoxville and Chattanooga. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
NCT05254171
Recruiting
The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), including subjects who have received prior neoadjuvant or adjuvant treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/04/2024
Locations: Tennessee Oncology NASH - SCRI - PPDS, Nashville, Tennessee
Conditions: Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
Register for Updates
eHealth Insomnia Intervention for Adult Survivors of Childhood Cancer
NCT04317742
Recruiting
There is evidence that survivors of childhood cancer have a high prevalence of poor sleep, including symptoms of insomnia. Insomnia is highly comorbid and has been associated with impaired cognitive performance, a range of psychiatric disorders, cardiovascular disease, and reduced quality of life. However, we still lack knowledge about the direct impact of available internet-based insomnia treatment programs for survivors of childhood cancer experiencing insomnia, in addition to how improving in... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
11/04/2024
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Childhood Cancer, Insomnia, Neurocognitive Impairment, Survivorship, Late Effect, Sleep
Register for Updates
Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body
NCT04248452
Recruiting
This phase III trial studies how well the addition of radiotherapy to the usual treatment (chemotherapy) works compared to the usual treatment alone in treating patients with esophageal and gastric cancer that has spread to a limited number of other places in the body (oligometastatic disease). Radiotherapy uses high energy x-rays, gamma rays, or protons to kill tumor cells and shrink tumors. Drugs used in usual chemotherapy, such as leucovorin, 5-fluorouracil, oxaliplatin, and capecitabine, wor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/04/2024
Locations: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
Conditions: Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Oligometastatic Esophageal Adenocarcinoma, Oligometastatic Gastric Adenocarcinoma, Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8
Register for Updates
High Vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
NCT05215327
Recruiting
Lung allograft recipients have a higher burden of influenza disease and greater associated morbidity and mortality compared with healthy controls. Induction and early maintenance immunosuppression is thought to impair immunogenicity to standard dose inactivated influenza vaccine. This early post-transplant period is when immunity is most desirable, since influenza disease during this time frame is associated with adverse consequences. Thus, strategies to reduce severe influenza disease in this h... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
10/31/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Immunization; Infection, Transplantation Infection, Influenza
Register for Updates
REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Minorities
NCT06399705
Recruiting
This is a research study in minorities to compare the outcomes of two procedures that restore blood flow to the arteries of the heart. In one procedure the blockages are ballooned and then stented with a small wire mesh tube through a small incision in the wrist or the groin. The other procedure is an open-heart operation in which healthy blood vessels from inside the chest, leg, and/or forearm are used to "bypass" the blockages (like a detour). Outcomes will be measured by comparing survival an... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2024
Locations: Methodist Le Bonheur Healthcare, Memphis, Tennessee
Conditions: Coronary Artery Disease
Register for Updates
REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Women
NCT06399692
Recruiting
This is a research study in women to compare the outcomes of two procedures that restore blood flow to the arteries of the heart. In one procedure the blockages are ballooned and then stented with a small wire mesh tube through a small incision in the wrist or the groin. The other procedure is an open-heart operation in which healthy blood vessels from inside the chest, leg, and/or forearm are used to "bypass" the blockages (like a detour). Outcomes will be measured by comparing survival and imp... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2024
Locations: Methodist Le Bonheur Healthcare, Memphis, Tennessee
Conditions: Coronary Artery Disease
Register for Updates
Otitis Treatment with OtoSight™ - Modification of Antibiotic Treatment Intervention in Children
NCT06285812
Recruiting
A pragmatic, mixed-method trial is to show the ability of OtoSight to change management of the pediatric patient presenting with ear pain in a way that improves patient outcomes and reduces costs.
Gender:
ALL
Ages:
Between 6 months and 17 years
Trial Updated:
10/30/2024
Locations: HealthStar Physicians, Morristown, Tennessee
Conditions: Otitis Media Acute
Register for Updates
A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis
NCT04973137
Recruiting
A Phase 3 study to evaluate the efficacy and safety of birtamimab plus standard of care compared to placebo plus standard of care in Mayo Stage IV patients with AL amyloidosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2024
Locations: University of Tennessee Medical Center, Knoxville, Tennessee
Conditions: Light Chain (AL) Amyloidosis
Register for Updates
Study of Individuals Affected With Hypoplasminogenemia
NCT03797495
Recruiting
This is an Investigator initiated retrospective and prospective single cohort study. The study will utilize an international registry and develop a specimen biobank to provide an improved understanding of the natural history of hyposplasminogenemia, to elucidate the heterogeneity of phenotypic expression, identify markers to predict disease course, and inform improved therapeutic modalities
Gender:
ALL
Ages:
All
Trial Updated:
10/30/2024
Locations: Vanderbilt Children's Hematology-Oncology, Nashville, Tennessee
Conditions: Plasminogen Deficiency
Register for Updates
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT05929768
Recruiting
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be bette... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: Baptist Memorial Hospital and Cancer Center-Collierville, Collierville, Tennessee
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Register for Updates
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old
NCT04551170
Recruiting
Pseudohypoparathyroidism is a genetic disorder with limited treatment options, characterized by early-onset obesity, short stature and resistance to multiple hormones. This phase 2 clinical trial and open-label extension study will test the efficacy of theophylline, a phosphodiesterase inhibitor, in pseudohypoparathyroidism. We hypothesize that theophylline will cause weight loss, slow the rate of growth plate closure and decrease hormone resistance in children.
Gender:
ALL
Ages:
Between 2 years and 12 years
Trial Updated:
10/29/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Pseudohypoparathyroidism, Albright Hereditary Osteodystrophy, Pseudohypoparathyroidism Type 1a
Register for Updates
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
NCT05352672
Recruiting
This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called REGN2810, also known as cemiplimab (each individually called a "study drug" or called "study drugs" when combined). The study is focused on patients with a type of skin cancer known as melanoma. The aims of the study are to see how effective the combination of fianlimab and cemiplimab are in treating the melanoma skin cancer, in comparison with a medicati... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
10/28/2024
Locations: University of Tennessee Medical Center, Knoxville, Tennessee
Conditions: Melanoma
Register for Updates